Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
Sana Biotechnology makes engineered cell medicines that replace or repair sick cells in the body.
Sana Biotechnology is a biotech company that is trying to turn cells into medicine. Its big idea is simple to say, hard to do: take cells from a donor, engineer them, and put them into a patient so the patient's body gets working replacement cells. If your liver or heart or pancreas cells are broken or missing, a fresh supply of lab-made cells could fix the problem. That is the pitch. Nobody has fully proven it yet, which is exactly why this is a risky, exciting kind of company.
Think of it like the difference between giving someone a spare part made just for them versus a mass-produced spare part that any car can use. Today's approved cell therapies mostly need your own cells, harvested and remade for you alone, which is slow and expensive. Sana is chasing off-the-shelf cells, made from donors in batches, so they can be shipped and used quickly. Its leader, Steve Harr, a former Goldman Sachs healthcare banker and doctor, took the company public in 2021, and Sana has kept its labs mostly near Seattle and in the Boston area. The catch is money and time. Sana does not sell anything yet, so it has no product revenue and instead runs on cash from investors. That means its survival depends on raising money and hitting milestones, like early human trials for its cell therapies in diabetes, cancer, and genetic diseases. If the science works, this could be a huge business; if it stumbles in trials or runs low on cash, the stock can fall fast. That is the whole story in one line: big scientific bet, no revenue yet, everything rides on the experiments.
Saved answer · last researched 15 Oct 2026
see a list of the most recent 300 searches below: